PharmaTher Holdings is building a range of 3D printed peptide products for a new U.S. compounding pathway. The first two are oral tablets of KPV and BPC-157 designed to release their dose in the colon. It is timed to the U.S. Department of Health and Human Services (HHS) policy that lets qualified Section 503A pharmacies…